Page 1 of 2 for Homburger, News & Features

Showing 1 - 10 of 17 for "" with applied filters

Filters:

Switzerland: Homburger advised Yoda PLC on Ultima Capital SA’s CHF 100 m common bond loan

07 January 2026 by Homburger - Switzerland

Homburger acted as counsel to Yoda PLC in respect of a new CHF 100 m common bond loan issued by Ultima Capital SA and subscribed for by National Bank of Greece S.A. Ultima Capital SA is a luxury real estate company that holds and develops a portfolio of high-end real estate assets in Switzerland, France and Greece.

News & Analysis

Switzerland: Homburger advises Windward Bio on licensing deal with Qyuns Therapeutics

23 December 2025 by Homburger - Switzerland

On December 21, 2025, Windward Bio Group AG, a Swiss-based private, clinical-stage biotechnology company committed to improving outcomes for people living with advanced immunological diseases, announced a licensing agreement between its affiliate, LE2025 Therapeutics AG, and Qyuns Therapeutics Co., Ltd. for the development and commercialization of WIN027 (also known as QX027N), a potential best-in-disease, long-acting bispecific antibody targeting TSLP and IL-13.

News & Analysis

Switzerland: Homburger advised Aris Mining Corporation on the acquisition of the remaining 49% interest in the joint venture with MDC Industry Holding Company LLC

16 December 2025 by Homburger - Switzerland

On December 12, 2025, Aris Mining Corporation (TSX: ARIS; NYSEA: ARMN) announced the completion of its acquisition of the remaining 49% interest in the Soto Norte joint venture in Colombia from MDC Industry Holding Company LLC (Mubadala)

News & Analysis

Switzerland: Homburger advises Biocorp on SK Capital’s investment in Swixx BioPharma

15 December 2025 by Homburger - Switzerland

On December 15, 2025, Swixx BioPharma AG announced the signing of an agreement for a strategic investment by SK Capital Partners.

News & Analysis

Switzerland: Homburger advises EQT on the sale of an additional 10% in Galderma to L’Oréal, reinforcing L’Oréal’s strategic investment in Galderma

08 December 2025 by Homburger - Switzerland

On December 8, 2025, EQT announced the sale of an additional 10% stake in Galderma Group AG (SIX: GALD) by a consortium led by EQT, which includes Sunshine SwissCo GmbH (SSCO), Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as sellers) to L’Oréal S.A.

News & Analysis

Switzerland: Homburger advised Roche on USD 1.9 bn in aggregate principal amount of senior notes, which were issued by Roche Holdings, Inc. and guaranteed by Roche Holding Ltd

04 December 2025 by Homburger - Switzerland

On December 2, 2025, Roche Holdings, Inc. successfully completed its issuance of USD 1.9 bn in aggregate principal amount of senior notes, consisting of USD 500 m 4.075% notes due 2030, USD 600 m 4.374% notes due 2032 and USD 800 m 4.666% notes due 2035.

News & Analysis

Switzerland: Homburger advised NVentures (NVIDIA) on its investment in Flexion Robotics

24 November 2025 by Homburger - Switzerland

On November 20, 2025, Flexion Robotics, a Zurich-based technology company, announced that it had raised USD 50 million in Series A funding from DST Global Partners, NVentures (NVIDIA’s venture capital arm), redalpine, Prosus Ventures, and Moonfire.

News & Analysis

Switzerland: Homburger advised UBS AG, acting through its London branch, on its issuance of EUR 750 m in aggregate principal amount of senior notes under its Euro Note Programme

24 November 2025 by Homburger - Switzerland

On November 21, 2025, UBS AG, acting through its London branch, successfully completed its issuance of EUR 750 m in aggregate principal amount of Floating Rate Notes due 2027 under its Euro Note Programme.

News & Analysis

Switzerland: Homburger advised UBS AG, acting through its Stamford branch, on its 3(a)(2) offering of USD 750 m Floating Rate Senior Notes

20 November 2025 by Homburger - Switzerland

On November 18, 2025, UBS AG, acting through its Stamford branch, successfully completed its issuance of USD 750 m in aggregate principal amount of Floating Rate Senior Notes due 2027 under its medium-term notes program.

News & Analysis

Switzerland: Homburger advised CDR-Life AG on a new global licensing agreement with Boehringer Ingelheim

12 November 2025 by Homburger - Switzerland

On November 4, 2025, CDR-Life and Boehringer Ingelheim announced a new global licensing agreement to develop CDR-Life’s unique antibody-based molecule CDR111 for autoimmune diseases.

News and features

Articles

Article type

Switzerland: Homburger advised Yoda PLC on Ultima Capital SA’s CHF 100 m common bond loan

Switzerland: Homburger advises Windward Bio on licensing deal with Qyuns Therapeutics

Switzerland: Homburger advised Aris Mining Corporation on the acquisition of the remaining 49% interest in the joint venture with MDC Industry Holding Company LLC

Switzerland: Homburger advises Biocorp on SK Capital’s investment in Swixx BioPharma

Switzerland: Homburger advises EQT on the sale of an additional 10% in Galderma to L’Oréal, reinforcing L’Oréal’s strategic investment in Galderma

Switzerland: Homburger advised Roche on USD 1.9 bn in aggregate principal amount of senior notes, which were issued by Roche Holdings, Inc. and guaranteed by Roche Holding Ltd

Switzerland: Homburger advised NVentures (NVIDIA) on its investment in Flexion Robotics

Switzerland: Homburger advised UBS AG, acting through its London branch, on its issuance of EUR 750 m in aggregate principal amount of senior notes under its Euro Note Programme

Switzerland: Homburger advised UBS AG, acting through its Stamford branch, on its 3(a)(2) offering of USD 750 m Floating Rate Senior Notes

Switzerland: Homburger advised CDR-Life AG on a new global licensing agreement with Boehringer Ingelheim